In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
about
The Antibiotic Drug Tigecycline: A Focus on its Promising Anticancer PropertiesTigecycline: first of a new class of antimicrobial agentsImpact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infectionsDiagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infectionsIn vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcyclineA randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infectionsAntimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobialEvaluation of a potential tigecycline-warfarin drug interaction.Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies.Clinical and microbiological characteristics of Eggerthella lenta bacteremiaPotential role of tigecycline in the treatment of community-acquired bacterial pneumonia.Identification and sequence of a tet(M) tetracycline resistance determinant homologue in clinical isolates of Escherichia coli.Clostridium difficile: improving the prevention paradigm in healthcare settings.Development and validation of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of tigecycline in rat brain tissues.Tigecycline: an evidence-based review of its antibacterial activity and effectiveness in complicated skin and soft tissue and intraabdominal infections.Development and validation of an LC-MS/MS method for the determination of tigecycline in human plasma and cerebrospinal fluid and its application to a pharmacokinetic study.Tigecycline for the treatment of infections due to resistant Gram-positive organisms.Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.Susceptibility of important Gram-negative pathogens to tigecycline and other antibiotics in Latin America between 2004 and 2010.The In Vitro Evaluation of Tigecycline and the In Vivo Evaluation of RPX-978 (0.5% Tigecycline) as an Ocular Antibiotic.Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections.Expression of Staphylococcus epidermidis SdrG increases following exposure to an in vivo environmentAnti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era.Pharmacologic options for CNS infections caused by resistant Gram-positive organisms.Impact of antibiotic resistance in gram-negative bacilli on empirical and definitive antibiotic therapy.In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for hospital acquired pneumonia.Tigecycline for the treatment of patients with community-acquired pneumonia requiring hospitalization.Inflammation and the host response to injury, a large-scale collaborative project: patient-oriented research core--standard operating procedures for clinical care VII--Guidelines for antibiotic administration in severely injured patients.Genetic Mechanisms of Antimicrobial Resistance of Acinetobacter baumannii.Efficacy and safety of tigecycline: a systematic review and meta-analysis.More Than Just Light: Clinical Relevance of Light Perception in the Nosocomial Pathogen Acinetobacter baumannii and Other Members of the Genus Acinetobacter.Tigecycline in febrile neutropenic patients with haematological malignancies: a retrospective case documentation in four university hospitals.In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest.Effect of proton pump inhibitors on in vitro activity of tigecycline against several common clinical pathogensPostantibiotic effect of tigecycline against 14 gram-positive organismsCapability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologiesValidation and reproducibility assessment of tigecycline MIC determinations by Etest.Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control
P2860
Q28076402-86C8A938-E6CB-4355-8029-39E1AD6273ADQ28253736-F9D4FF07-9891-41FC-B148-2A9CC4283B4DQ33676144-4E95F61E-DD85-46D0-B0DA-9AD6A66FDCABQ34352287-F3E90972-AE00-4593-A471-7A4A9446127FQ34389235-9D9769EC-9C06-48AB-8C63-A17F95CBCE7FQ34474973-31E78C81-7DDF-4B4F-BB1B-BB3F733EB7FDQ34569412-AEED8D4F-210F-4E5F-907E-74A36829638EQ34593514-6083ACC7-53A8-4909-9BA2-DD43CAA80B07Q34803735-3EEAADBE-7CF8-47EF-AF35-173604DCAC98Q34983043-0E306DBA-F518-486E-AF43-F2A8AC754F51Q35026616-6A9E6F81-0088-4C2E-B043-14FD80E41481Q35130141-376AB0B4-6FF8-4191-BC94-A0E0018C7B03Q35222472-9C87EDD1-4B78-4945-BCC6-9A408EB67ECFQ35778366-E9A774E8-2626-4E2F-87F5-ECC8FDE2E748Q35876393-30E50446-E505-47A4-BCDB-40B930671955Q36035161-7788787C-7A09-44BE-A369-3B6E977B65A9Q36376443-9A3F45CB-9CAC-4713-80C9-2D32C2A11EAEQ36382134-4C67A141-7673-42A3-A6A6-9C0520C4614AQ36402271-05E423DD-BEFE-4F2C-8325-1E8ADFF311B3Q36656768-507C8A8D-DD7A-4A32-A160-1E46E8F814CDQ36663656-2C8ECF5D-F7D0-4CBF-A700-1AD62413C1AAQ36747096-9F2D3F81-F790-47C6-BE03-F216C4A08FBAQ36763997-196B86C0-647F-421F-A47D-154D24A0AB08Q36967265-E8CF722E-99FF-48D0-A5D9-1F6C2B4006A7Q37077629-CCD20040-17E8-4C8F-9100-C25F3AF10069Q37247110-04A13823-685B-44A3-B54C-0D375981D72CQ37481794-5B8C9209-3C20-4301-A182-4603406F24F2Q37608268-02D6464D-E54F-49B3-90AD-402BA170CE0DQ37731193-AB617C20-C61A-4057-9806-656B97A350B2Q37838117-A3FA38B2-0CBF-4112-BC45-9B10BE35D41DQ37891606-0253E3A5-3263-4AB4-B2DB-4F1C579E1377Q38572833-32468771-B7C1-4259-9282-6C1F016228A5Q40236833-35B42611-DF29-4236-B4AB-68ECF62BDA5DQ40241381-F096E570-7C6B-4F5A-B03E-787445953146Q41811933-2BD56546-5910-482F-8200-2835CD2ED03DQ41882996-1A8C8F4F-5986-4B6A-9865-7D75312B8C2CQ41968686-D414D5E1-2236-420A-BAEE-179B4BD228BAQ42112086-F1EAA31E-5892-43EB-A912-1218F65B4D64Q42412999-8A789C3E-8F92-4483-85F7-9BC6F599F91AQ42432332-3A60BC42-0033-4C58-AD0B-94D24E1BDC67
P2860
In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
In vitro activity of tigecycli ...... ed intra-abdominal infections.
@en
In vitro activity of tigecycli ...... ed intra-abdominal infections.
@nl
type
label
In vitro activity of tigecycli ...... ed intra-abdominal infections.
@en
In vitro activity of tigecycli ...... ed intra-abdominal infections.
@nl
prefLabel
In vitro activity of tigecycli ...... ed intra-abdominal infections.
@en
In vitro activity of tigecycli ...... ed intra-abdominal infections.
@nl
P2860
P356
P1476
In vitro activity of tigecycli ...... ed intra-abdominal infections.
@en
P2093
D Tasha Weaver-Sands
Peter J Petersen
P2860
P304
P356
10.1086/431673
P407
P478
41 Suppl 5
P577
2005-09-01T00:00:00Z